FDA To Hold COX-2 Advisory Committee In Early 2005, Woodcock Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will have to make a trade-off between getting products on the market and determining their cardiovascular safety profile. Merck believes placebo-controlled trials in osteoarthritis patients should not be longer than four months due to ethical concerns.
You may also be interested in...
Celebrex, Bextra Given Breathing Room In Latest FDA Advisory
Agency suggests any regulatory action on COX-2s or non-selective NSAIDs will wait until after a February advisory committee meeting. A public health advisory urges physicians to consider the “emerging” information on cardiovascular risk when prescribing COX-2s. FDA also orders a review of all prevention studies using Pfizer’s Celebrex and Bextra.
Celebrex, Bextra Given Breathing Room In Latest FDA Advisory
Agency suggests any regulatory action on COX-2s or non-selective NSAIDs will wait until after a February advisory committee meeting. A public health advisory urges physicians to consider the “emerging” information on cardiovascular risk when prescribing COX-2s. FDA also orders a review of all prevention studies using Pfizer’s Celebrex and Bextra.
COX-2 Advisory Committee Review Will Include New Celebrex Safety Data
Committee will also “explore ways of further evaluation” of the safety of Pfizer’s Bextra and COX-2s approved in Europe, such as Merck’s Arcoxia. FDA also expects discussion of broader NSAID category, at least for “context.”